Operating Income (Loss) in USD of CRISPR Therapeutics AG from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
CRISPR Therapeutics AG quarterly/annual Operating Income (Loss) history and change rate from 2014 to Q3 2025.
  • CRISPR Therapeutics AG Operating Income (Loss) for the quarter ending September 30, 2025 was -$132M, a 19.9% decline year-over-year.
  • CRISPR Therapeutics AG Operating Income (Loss) for the twelve months ending September 30, 2025 was -$574M, a 72.8% decline year-over-year.
  • CRISPR Therapeutics AG annual Operating Income (Loss) for 2024 was -$467M, a 110% decline from 2023.
  • CRISPR Therapeutics AG annual Operating Income (Loss) for 2023 was -$223M, a 66.9% increase from 2022.
  • CRISPR Therapeutics AG annual Operating Income (Loss) for 2022 was -$673M, a 280% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

CRISPR Therapeutics AG Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$574M -$132M -$21.9M -19.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$552M -$229M -$78.1M -51.6% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-04
Q1 2025 -$474M -$148M -$7.84M -5.57% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q4 2024 -$467M -$64.6M -$134M -193% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-11
Q3 2024 -$332M -$110M +$22.3M +16.8% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$355M -$151M -$56M -58.8% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-04
Q1 2024 -$299M -$141M -$76.1M -118% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q4 2023 -$223M $69.6M +$201M Oct 1, 2023 Dec 31, 2023 10-K 2025-02-11
Q3 2023 -$424M -$132M +$50M +27.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$474M -$95.2M +$88M +48% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$562M -$64.5M +$111M +63.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$673M -$132M +$14.2M +9.72% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-11
Q3 2022 -$687M -$182M -$53.5M -41.6% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$634M -$183M -$946M -124% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $312M -$176M -$61.4M -53.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $374M -$146M -$37.9M -35.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $411M -$129M -$36.5M -39.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $448M $763M +$843M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$395M -$115M -$41M -55.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$354M -$108M -$119M -1081% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-16
Q3 2020 -$236M -$92.4M -$232M -166% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$4.13M -$80.7M -$25.7M -46.8% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $21.6M -$73.6M -$25.2M -52% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 $46.7M $11M +$56.2M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-16
Q3 2019 -$9.47M $139M +$189M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-16
Q2 2019 -$198M -$55M -$17.7M -47.5% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-16
Q1 2019 -$180M -$48.4M -$21.4M -79.4% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-16
Q4 2018 -$159M -$45.2M -$46.2M -4753% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-12
Q3 2018 -$113M -$49.4M -$25.9M -110% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-12
Q2 2018 -$86.9M -$37.3M -$16M -75% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-12
Q1 2018 -$70.9M -$27M -$6.25M -30.1% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-12
Q4 2017 -$64.6M $972K +$26.3M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-25
Q3 2017 -$90.9M -$23.6M -$8.96M -61.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-25
Q2 2017 -$82M -$21.3M -$4.75M -28.7% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-25
Q1 2017 -$77.2M -$20.7M -$9.09M -78% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-25
Q4 2016 -$68.1M -$25.3M -$13.1M -108% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$55M -$14.6M -$8.41M -136% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$46.6M -$16.6M -$12.9M -357% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$33.6M -$11.7M -$7.92M -212% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$25.7M -$12.2M Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 -$6.2M Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 -$3.63M Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 -$3.74M Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10

CRISPR Therapeutics AG Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$467M -$244M -110% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-11
2023 -$223M +$451M +66.9% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-11
2022 -$673M -$1.05B -280% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-11
2021 $374M +$728M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 -$354M -$401M -858% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $46.7M +$206M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 -$159M -$94.3M -146% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 -$64.6M +$3.48M +5.11% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 -$68.1M -$42.4M -165% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
2015 -$25.7M -$19.1M -288% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$6.63M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.